Translate
Oric Pharmaceuticals, Inc.
About
8.32USD-0.14 -1.65%
Closed • Updated at 12:54 GMT+00:00Market Cap$861.27M
Volume795.2K
Beta-0.16
RSI37.35
Oric Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 4 2026
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
Apr 17 2026
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Mar 31 2026
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
Mar 27 2026
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
Mar 17 2026
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Recent Videos
The Biotech Short Attack: Decoding the ORIC Pharmaceuticals Plunge on April 1, 2026
Apr 01, 2026
ORIC Pharmaceuticals Rinzimetostat Dose Optimization Data Update Call | March 31, 2026
Apr 01, 2026
Oric Pharmaceuticals Inc. 2025 annual report
Feb 24, 2026
ORIC STOCK : POTENTIAL UPMOVE | ORIC PHARMACEUTICAL STOCK
Feb 14, 2026
Community Chat
Ask AI
Try asking